dr. robson on exploratory analysis from olympiad in breast cancer
Published 6 years ago • 254 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
1:15
dr. robson on the toxicity profile of olaparib in breast cancer
-
1:05
mark e. robson on breast cancer risk management
-
3:31
distinguishing between parp inhibitors in breast cancer
-
9:21
dr. litton on activity of talazoparib in advanced brca1/2 breast cancer
-
1:10
dr. tripathy on impact of olaparib approval in brca-positive breast cancer
-
7:42
breast cancer: genomic testing for adjuvant therapy
-
5:49
perspectives on the olympia study of adjuvant olaparib in early breast cancer | nadine tung
-
2:21
olaparib: predicting response in breast cancer
-
3:05
exploring the use of olaparib in advanced breast cancer
-
1:16
parp inhibitors improve outcomes, qol in breast cancer
-
1:09
dr. rao on the soft trial in patients with premenopausal breast cancer
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
2:18
the importance of the olympia trial for breast cancer patients
-
2:21
dr. rafii discusses clinical outcomes with olaparib in patients with ovarian cancer
-
1:13:35
2021 best of breast | case 1 genomic testing
-
2:19
treatment optimization trials in breast cancer
-
8:09
olaparib improves disease-free survival in high-risk early-stage her2-negative breast cancer wit...
-
10:42
fda approvals of a biosimilar and dtc genetic test, breakthrough designation in mzl, and more
-
0:51
how does olaparib affect the quality of life of breast cancer patients?